molecules of the month


oral pan-coronavirus antiviral, rev. covalent

Ph. III candidate for COVID-19 (300 mg BID)

from SARS-CoV-1 inhibitor (WO2005113580)


Pfizer Worldwide Research

Chemical structure of Pfizer’s PF-07321332 (API of Paxlovid)
2 mins read

1.  This month’s cover molecule, Pfizer’s PF-07321332 (API of Paxlovid) is an oral, reversible covalent SARS-CoV-2 main protease inhibitor, which has been submitted to the FDA by Pfizer for emergency approval for Covid treatment. Interim data showed Paxlovid reducing Covid hospitalization and death by 89%. It was nominated for this month’s cover by Mike Koehler, Christian Kuttruff, and Callie Bryan. “Paxlovid sets a speed record in development that may never be broken!” says Mike Koehler. Their Science paper describing the development came out in the same month that their clinical trial was ended early due to strong efficacy. Paxlovid may be more important now that molnupiravir showed sharply reduced efficacy in the final analysis of its trial data relative to the interim analysis.…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: